IP Library Granted Patent US 12693289
Granted Patent B2
US 12693289 · App. 18/200,591 · Granted Jul 28, 2026

Application of compounds in the preparation of reagents for down-regulation of RUNX2

Inventors: Wuguang Pan (Guangzhou, CN); Wei Zhu (Guangzhou, CN)
Assignee: Geneheal Biotechnology Co., Ltd.
G01N33/5011A61K31/5383A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12693289
App. No.
18/200,591
Granted
Jul 28, 2026
Kind
B2
Abstract

The present invention discloses application of compounds in the preparation of reagents for down-regulation of Runx2. The inventors have confirmed through computational studies and disease models that Fostamatinib, Regorafenib and melatonin can significantly down-regulate the expression of Runx2, and have a significant targeted therapeutic effect on cancers with abnormally high expression of Runx2, and are efficient reagents for reducing the expression of Runx2. Especially the Runx2 expression down-regulation reagent used in the laboratory.

Claims (13)

1 . A method for treating tumor of a patient, comprising:

a) obtaining a sample from the patient with a tumor;

b) determining the level of Runx2 in the sample; and

c) diagnosing the patient as being likely to be responsive to a treatment compound if the level of Runx2 in the sample is significantly higher than a reference level of the Runx2;

d) administering to the patient in need thereof with a therapeutically effective amount of Fostamatinib or a pharmaceutically acceptable salt thereof,

wherein the Fostamatinib or pharmaceutically acceptable salt thereof down-regulates the expression of Runx2 for treating tumor of the patient.

2 . The method of claim 1 , wherein said reference level of the Runx2 is the level of the Runx2 of the normal tissue of the patient.

3 . The method of claim 1 , wherein the pharmaceutically acceptable salt is an acid salt or a base addition salt.

4 . The method of claim 1 , wherein said tumor is hepatoma or lung cancer.

5 . The method of claim 2 , wherein said tumor is hepatoma or lung cancer.

6 . The method of claim 3 , wherein said tumor is hepatoma or lung cancer.

7 . The method of claim 3 , wherein the acid is selected from a group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetylamino benzoic acid, butyric acid, (+)-camphoric acid, camphor sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, hexanoic acid, octanoic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid, glutamic acid, α-ketoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, maleic acid, malic acid, (−)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxyl-2-naphthoic acid, nicotinic acid, nitric acid, oletic acid, orotc acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-aminosalicyl benic acid, b stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, sulfocyanic acid, p-toluenesulfonic acid, undecylenic acid, pentanoic acid, and acylated amino acid.

8 . The method of claim 3 , wherein the base is a hydroxide of an alkali metal or alkaline earth metal.